Missouri AG tells Lilly to halt hospital data demands for 340B discounts

Missouri’s attorney general has told Eli Lilly to stop making hospitals provide claims data to access discounted medicines under the federal 340B programme, according to STAT. The warning reflects a broader trend of state officials challenging pharmaceutical companies’ requirements tied to drug discount access.

This development matters for pharma and healthcare executives because it signals a shift in how states may regulate data collection and discount eligibility. More states could follow Missouri’s lead, increasing compliance risks and operational uncertainty for drugmakers and hospitals alike.